company_name|ticker|filing_time|new_product|description
THERMO FISHER SCIENTIFIC INC|TMO|February 25, 2025|Purification and Filtration Business Acquisition by Solventum Corporation|Purification and filtration business.
Boston Scientific Corp|BSX|November 15, 2024|Not applicable (only a general statement)|Completed acquisition of Axonics Inc.
THERMO FISHER SCIENTIFIC INC.|TMO|February 25, 2025|Description: Purification and filtration business|Purification and filtration business
Neurocrine Biosciences Inc|NBIX|December 20, 2024|CrenessityTM/Crinecerfont capsules and oral solution|Available in the United States.
LIGAND PHARMACEUTICALS INC|LGND|June 27, 2024|OHTUVAYRETM|The first inhaled product with a novel mechanism of action available for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients in more than 20 years.
Spectrum Brands Holdings, Inc.|SPB|May 23, 2024|Description: Structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and to the extent the company or a guarantor is not a holder thereof preferred equity, if any, of the company or that guarantors subsidiaries.|Structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and to the extent the company or a guarantor is not a holder thereof preferred equity, if any, of the company or that guarantors subsidiaries.
LIGAND PHARMACEUTICALS INC|LGNDZ|June 27, 2024|Ohtuvayretm (Ensifentrine)|The first inhaled product with a novel mechanism of action available for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients in more than 20 years.
LIGAND PHARMACEUTICALS INC|LGNZZ|June 27, 2024|Ohtuvayretm (Ensifentrine) for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD)|The first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD.
